COVID-19 Vaccines: A Radiological Review of the Good, the Bad, and the Ugly

Ishan Kumar1 Mohammad Sharoon Ansari1 Ashish Verma1 Pramod Kumar Singh1 Sankha Shubhra Chakrabarti2 Ram Chandra Shukla1

1 Department of Radiodiagnosis and Imaging, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
2 Department of Geriatrics, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

Introduction

It has been almost 4 years since the first case of COVID-19 was reported. The disease has infected nearly 650 million people and claimed more than 6 million lives to date. The disease has profoundly affected the geopolitical, socioeconomic, and public health structure of the world and continues to do so. It was very soon realized that an effective vaccine is the only solution for this calamity and within a year from the beginning of this pandemic, several research teams developed vaccines against SARS-CoV-2. The vaccination drive that started in December 2020 reached an unprecedented scale within months and within almost 2 years, more than 13 billion doses had been distributed globally with 68.5% of the world population receiving at least one dose of a COVID-19 vaccine.

COVID-19 vaccines have been proven to be an effective tool to bring the pandemic under control. But despite their proven efficacy and safety, COVID-19 vaccines initially did not find widespread acceptance, particularly due to the phenomenon of vaccine hesitancy, defined by the World Health Organization (WHO) as a delay in acceptance or refusal of vaccines despite the availability of vaccination services.1 Reasons for COVID-19 vaccine hesitancy and acceptance are determined by a complex interplay of many factors, with different countries having different vaccine hesitancy factors. However, lack of visible proof of vaccine effectiveness and concerns related to vaccine-associated adverse events have been important factors affecting vaccine hesitancy, particularly because most of the COVID-19 infections are either asymptomatic or mild, and the pace with which COVID-19 vaccines have been developed and deployed for general population use. In general, vaccine development takes approximately 15 years; therefore, the speed of development of COVID-19 vaccine within 1 year contributed to vaccine hesitancy.2,3

Abstract

The World Health Organization has declared “with great hope” an end to COVID-19 as a public health emergency. The vaccination drive that started in December 2020 played a crucial role in controlling the pandemic. However, the pace at which COVID-19 vaccines were developed and deployed for general population use led to vaccine hesitancy, largely owing to concerns regarding the safety and efficacy of the vaccines. Radiology has been instrumental in demonstrating the extent of pulmonary involvement and identification of the complications of COVID-19, and the same holds true for vaccine-related complications. This review summarizes the existing body of radiological literature regarding the efficacy, adverse events, and imaging pitfalls that accompany the global rollout of various COVID-19 vaccines.
Radiology has been very instrumental in demonstrating the extent of pulmonary involvement, identification of complications, and even early diagnosis of COVID-19. High-resolution computed tomography (HRCT) of lungs provided an objective method in assessing the volume of lungs involved in a case of COVID-19 utilizing various semiquantitative scores. Moreover, radiological investigations were key in diagnosing various abdominal, cardiovascular, neurological, and musculoskeletal complications, especially potentially lethal pulmonary thromboembolism (PTE). Magnetic resonance imaging (MRI) provided important information about the extent of involvement of rhino-orbital-cerebral mucormycosis (ROCM) and HRCT was used to diagnose secondary fungal and other bacterial infections affecting the lung and guide the management of these confections. The field of radiology is uniquely poised to assess both the advantages and various adverse effects of vaccinations. A comprehensive radiological appraisal of the effects of the COVID-19 vaccine can yield crucial information that can provide a roadmap for the future management course of the pandemic. The benefits of a comparative review include providing an opportunity to establish the efficacy of vaccines in terms of involvement of pulmonary parenchyma by SARS-CoV-2 and secondarily identifying the possible adverse events and their radiological manifestations. This review encompasses information provided by the existing body of radiological literature regarding the efficacy, adverse events, and imaging pitfalls that accompany the global rollout of various COVID-19 vaccines.

**Radiological Assessment of Efficacy of COVID-19 Vaccines**

Chest radiographs have relatively low sensitivity for detecting COVID-19 pneumonia; however, these are vital imaging tools for continuous monitoring of disease severity progression. The Brixia score is a semiquantitative score employed from frontal radiographs to assess the disease severity of COVID-19. In this scoring system, both lungs are divided into three zones each (upper, middle, and lower), and a score of 0 to 3 is assigned to each zone (score 0: no lung abnormalities; score 1: interstitial infiltrates; score 2: interstitial predominance; score 3: alveolar predominance) and a total score out of 18 is allotted. HRCT is the most sensitive modality to assess pulmonary involvement, and typical findings seen are bilateral, peripheral ground-glass opacities (GGOs) with or without overlapping areas of consolidation, or associated interlobular septal thickening. Various scoring systems are used for assessing the severity of lung involvement in CT. The most commonly used CT severity scoring systems are the following:

- **CT visual quantitative score (scale 0–25):** scores of 1 to 5 are assigned according to the percentage of involvement (score 1: <5%; score 2: 5–25%; score 3: 25–49%; score 4: 50–74%; and score 5: >75%) in five anatomical lobes of the lungs, that is, right upper, right middle, right lower, left upper, and left lower lobes.
- **Chest CT severity score (scale 0–40):** scores of 0–2 are assigned according to percentage of involvement (score 0: no involvement; score 1: <50%; score 2: ≥50% involvement) in 18 anatomical segments of the lung with an additional division of the apicoposterior segment of the left upper lobe into apical and posterior divisions and anteromedial segment of the left lower lobe into anterior and medial segments.

Several studies assessed the safety and efficacy of COVID-19 vaccines that are being administered and have shown that the administration of vaccines scales down the disease severity in COVID-19 along with an effect on the systemic inflammatory and coagulopathic responses. However, there is a relative paucity of radiological data to provide substantial evidence of the reduction of the extent of pulmonary involvement to document the effectiveness of the vaccines. Table 1 summarizes the results of the radiological studies documenting the comparison between pulmonary involvement in unvaccinated patients and partially or completely vaccinated individuals who acquired breakthrough COVID-19 infection. The largest such study has been published by Verma et al from our institution involving 826 patients (581 unvaccinated, 196 single-dose incomplete vaccination, and 49 two-dose complete vaccination), using CT severity score (scale 0–40) as an imaging surrogate of the biological activity of the virus. The study demonstrated that patients receiving both doses of the SARS-CoV-2 vaccine showed lower CT severity scores in comparison to unvaccinated individuals or those who received only one dose of vaccine. Also, the mean severity scores were significantly lesser in younger patients (<60 years). Among the various radiological findings, GGOs and consolidations were significantly less in the vaccinated group, while other findings such as fibrosis, discoid atelectasis, and halo were similar in both groups. Similar results have been observed in the studies by Dubey et al and Lee et al demonstrating the efficacy of complete vaccination. As opposed to these studies, a study by Gurumurthy et al showed that vaccination results in lower CT scores regardless of complete two-dose vaccination or partial one-dose vaccination. Few of the studies have demonstrated similar results using chest X-ray-based Brixia score, which was significantly lower in vaccinated patients.

Granata et al made an interesting observation in their study on aerated residual lung volume (%) calculated by automated software using CT scan images in different strains of COVID. The study demonstrated that for the Delta variant, the aerated residual lung volume percentage is significantly higher in individuals vaccinated with at least two doses. However, for the Omicron variant, the residual aerated lung percentage was higher in patients inoculated with three doses, whereas vaccination with two doses did not improve lung aeration.

Very few studies have compared the extent of pulmonary involvement between the types of vaccines. In the study by Verma et al, a comparison between two vaccine types showed that the mean CT severity score was significantly lower in patients receiving nonreplicating viral vector vaccine (ChAdOx1-S, Covishield, AstraZeneca, University of Oxford) compared to those receiving inactivated virus vaccine (BBV152, Covaxin, Bharat Biotech). However, the latter group was very small in their study. Another study...
<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Study population</th>
<th>Key radiological findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verma et al&lt;sup&gt;8&lt;/sup&gt;</td>
<td>826</td>
<td>Vaccinated (&lt;i&gt;n&lt;/i&gt; = 245) • Nonreplicating viral vector vaccine ChAdOx1-S (&lt;i&gt;n&lt;/i&gt; = 209) • Inactivated virus vaccine BBV152 (&lt;i&gt;n&lt;/i&gt; = 36)</td>
<td>Completely vaccinated (&lt;i&gt;n&lt;/i&gt; = 49) Partially vaccinated (&lt;i&gt;n&lt;/i&gt; = 196) Unvaccinated (&lt;i&gt;n&lt;/i&gt; = 581)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CT severity score (0–40 scale): • Mean score was significantly lower in completely vaccinated patients (3.5 ± 6.3) vis-à-vis incompletely vaccinated (10.1 ± 10.5) and nonvaccinated (10.1 ± 11.4) patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• The mean CT scores were significantly lower in vaccinated patients of lower ages (&lt;60 y), while patients &gt;60 y did not show significantly different CT scores between the vaccinated and nonvaccinated groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Consolidations and ground-glass opacities were significantly lower in the group receiving complete vaccination as compared to the unvaccinated and incompletely vaccinated patients</td>
</tr>
<tr>
<td>Lee et al&lt;sup&gt;9&lt;/sup&gt;</td>
<td>761</td>
<td>Vaccinated (&lt;i&gt;n&lt;/i&gt; = 47) Unvaccinated (&lt;i&gt;n&lt;/i&gt; = 587)</td>
<td>In 412 patients who underwent chest CT examination during hospitalization, absence of pneumonia was seen in 59% of fully vaccinated patients and 22% of unvaccinated patients</td>
</tr>
<tr>
<td>Vicini et al&lt;sup&gt;10&lt;/sup&gt;</td>
<td>467</td>
<td>Vaccinated (&lt;i&gt;n&lt;/i&gt; = 251) • BNT162b2 mRNA (&lt;i&gt;n&lt;/i&gt; = 167) • ChAdOx1-S adenovirus vector (&lt;i&gt;n&lt;/i&gt; = 84) Unvaccinated (&lt;i&gt;n&lt;/i&gt; = 216)</td>
<td>Absence of pneumonia: • 15% in unvaccinated patients; 29% in ChAdOx1-S group and 51% with BNT162b2 vaccine Mean CT score (0–25 scale): • Significantly higher in unvaccinated patients (9.7 ± 6.1) than in the BNT162b2 (5.2 ± 6.1) or ChAdOx1-S (6.2 ± 5.9) group</td>
</tr>
<tr>
<td>Hanafi et al&lt;sup&gt;11&lt;/sup&gt;</td>
<td>60</td>
<td>Vaccinated (&lt;i&gt;n&lt;/i&gt; = 30) Unvaccinated (&lt;i&gt;n&lt;/i&gt; = 30)</td>
<td>Chest X-ray Brixia score (0–18): • Mean score significantly lower in the vaccinated group (1.53 + 1.27) compared to the unvaccinated patients (6.0 + 2.61)</td>
</tr>
<tr>
<td>Borghesi et al&lt;sup&gt;12&lt;/sup&gt;</td>
<td>205</td>
<td>Vaccinated (&lt;i&gt;n&lt;/i&gt; = 109) Unvaccinated (&lt;i&gt;n&lt;/i&gt; = 96)</td>
<td>Chest X-ray Brixia score (0–18): • Median score significantly lower in the vaccinated group (median: 1; IQR: 0–6) compared to the unvaccinated group (median: 5; IQR: 3–7)</td>
</tr>
<tr>
<td>Rahman et al&lt;sup&gt;13&lt;/sup&gt;</td>
<td>50</td>
<td>Vaccinated (&lt;i&gt;n&lt;/i&gt; = 50)</td>
<td>CT score (0–25 scale): 0 in 14% cases; 1–8 in 46%; 9–14 in 22% cases, and &gt;15 in 18% cases</td>
</tr>
<tr>
<td>Lakhia et al&lt;sup&gt;14&lt;/sup&gt;</td>
<td>229</td>
<td>Vaccinated (&lt;i&gt;n&lt;/i&gt; = 67) • Completely vaccinated (&lt;i&gt;n&lt;/i&gt; = 29) • Partially vaccinated (&lt;i&gt;n&lt;/i&gt; = 38) Unvaccinated (&lt;i&gt;n&lt;/i&gt; = 162)</td>
<td>CT score (0–25 scale): • Median CT score significantly lower in the completely vaccinated group (median: 0; IQR: 0–3) compared to the partially vaccinated group (median: 3.5; IQR: 0–9) and the unvaccinated group (median: 10; IQR: 7–14)</td>
</tr>
<tr>
<td>Granata et al&lt;sup&gt;15&lt;/sup&gt;</td>
<td>71</td>
<td>Vaccinated (&lt;i&gt;n&lt;/i&gt; = 31) • Delta variant (&lt;i&gt;n&lt;/i&gt; = 18) • Omicron (&lt;i&gt;n&lt;/i&gt; = 13) Unvaccinated (&lt;i&gt;n&lt;/i&gt; = 40) Delta variant (&lt;i&gt;n&lt;/i&gt; = 20) Omicron (&lt;i&gt;n&lt;/i&gt; = 20)</td>
<td>Median value of (range) of aerated residual lung volume (%) calculated by automated software using CT scan images In Delta variant • Significantly lower median values in the unvaccinated group (median: 46.7; IQR: 13.60–75.60) compared to those vaccinated with two doses (median: 67.10;</td>
</tr>
</tbody>
</table>

(Continued)
but the association appears unclear. Myocardial infarction and arrhythmias have been reported, cardiac complication of COVID-19 vaccination, few cases of vaccines. While myopericarditis has been the most common reactions has been reported all over the world after various vaccination for COVID-19, a spectrum of cardiac complications has been reported all over the world after various vaccines. With such an unprecedented level of mass vaccination for COVID-19, a spectrum of cardiac complications related to hepatitis B, smallpox, and Haemophilus influenzae vaccines were reported. Myocarditis is the most commonly described cardiac complication after receiving these vaccines. With such an unprecedented level of mass vaccination for COVID-19, a spectrum of cardiac complications has been reported all over the world after various vaccines. While myopericarditis has been the most common cardiac complication of COVID-19 vaccination, few cases of myocardial infarction and arrhythmias have been reported, but the association appears unclear. Myocarditis/Pericarditis
As per the data provided by the Advisory Committee on Immunization Practices, 1,226 reports of probable myocarditis/pericarditis have been reported after administration of 300 million COVID-19 mRNA vaccine doses till June 2021, two-thirds of which followed the second dose. Several mechanisms like hyperimmune response, aberrant nonspecific innate immune response, molecular mimicry, or functional autoantibodies, etc., have been postulated for postvaccination myocarditis. The clinical features were mostly mild chest pain and most of the patients improved without any treatment other than supportive measures and rest. Symptoms typically started within 1 week after vaccination (median of 3 days from the second dose in 81% of patients). Electrocardiographic (ECG) changes are nonspecific and the majority of patients had ST- or T-wave changes, and/or elevated cardiac enzymes. Cardiac MRI plays an important role in the evaluation of acute myocarditis, and the diagnosis of myocarditis on MRI is based on the 2018 Revised Lake Louise consensus criteria.

### Imaging of COVID-19-Related Vaccine Complications

#### Cardiovascular Complications
Before the COVID-19 pandemic, cardiac complications related to hepatitis B, smallpox, and Haemophilus influenzae vaccines were reported. Myocarditis is the most common reported cardiac complication after receiving these vaccines. With such an unprecedented level of mass vaccination for COVID-19, a spectrum of cardiac complications has been reported all over the world after various vaccines. While myopericarditis has been the most common cardiac complication of COVID-19 vaccination, few cases of myocardial infarction and arrhythmias have been reported, but the association appears unclear. Myocarditis/Pericarditis
As per the data provided by the Advisory Committee on Immunization Practices, 1,226 reports of probable myocarditis/pericarditis have been reported after administration of 300 million COVID-19 mRNA vaccine doses till June 2021, two-thirds of which followed the second dose. Several mechanisms like hyperimmune response, aberrant nonspecific innate immune response, molecular mimicry, or functional autoantibodies, etc., have been postulated for postvaccination myocarditis. The clinical features were mostly mild chest pain and most of the patients improved without any treatment other than supportive measures and rest. Symptoms typically started within 1 week after vaccination (median of 3 days from the second dose in 81% of patients). Electrocardiographic (ECG) changes are nonspecific and the majority of patients had ST- or T-wave changes, and/or elevated cardiac enzymes. Cardiac MRI plays an important role in the evaluation of acute myocarditis, and the diagnosis of myocarditis on MRI is based on the 2018 Revised Lake Louise consensus criteria.

### Table 1 (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Study population</th>
<th>Key radiological findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gurumurthy et al16</td>
<td>306</td>
<td>Vaccinated (n = 163) ChAdOx1-S adenovirus vector (n = 107) Inactivated virus vaccine BBV152 (n = 56) • Completely vaccinated (n = 39) • Partially vaccinated (n = 124) Unvaccinated (n = 143)</td>
<td>CT score (0–25 scale): • Mild CT score (&lt;7) was significantly in higher percentage in the vaccinated group (31%) than in the unvaccinated group (11.9%) • No significant difference between partially vaccinated (single-dose) and completely vaccinated (double-dose) groups</td>
</tr>
<tr>
<td>Dubey et al17</td>
<td>200</td>
<td>Vaccinated (n = 100) • Completely vaccinated (n = 73) • Partially vaccinated (n = 27) Unvaccinated (n = 100)</td>
<td>CT score (0–25 scale): • Median score was significantly lower in the vaccinated group (median: 7; range: 0–24) compared to the unvaccinated group (median: 13; range: 1–25) • The median score of the fully vaccinated group was lower than that of the partially vaccinated individuals (6 vs. 9)</td>
</tr>
</tbody>
</table>

Abbreviations: CT; computed tomography; IQR, interquartile range.
showed that there is no significant difference in the pattern of the myocardial findings at cardiac MRI in COVID-19-vaccine-associated myocarditis compared to other causes of myocarditis including COVID-19. The common findings on MRI are T2 wall hyperintensity (77%), subepicardial LGE (62%), mid-wall LGE (20%), pericardial enhancement (43%), and effusion/edema (19%). Subendocardial/transmural LGE was not reported in this study; however, others have reported isolated cases of subendocardial LGE. Less severe functional impairment, lower T1 signal, and less frequent involvement of the septum have been observed in COVID-19-vaccine-associated myocarditis compared to other forms of myocarditis. Patel et al demonstrated that septal LGE and mid-wall LGE involvements were more common in other cases of myocarditis compared to COVID-19-vaccine-associated myocarditis. No significant difference in myocardial injury patterns among different COVID-19 vaccines has been noted. Nonhospitalized patients with myocarditis had MRI abnormalities comparable to those needing hospital admission for vaccine-associated myocarditis. Even the extent of late gadolinium enhancement in the vaccine group was lower and abnormalities on tissue characterization (T1 and T2 mapping) were less severe relative to the other groups. In a series of 15 pediatric patients (<19 years) with suspected myocarditis following the Pfizer vaccine, LGE was observed in 12 children (80%).

**Acute Coronary Syndrome**

Few studies have reported cases of myocardial infarction resulting from coronary artery disease occurring within 24 hours of receiving the first dose of mRNA vaccines. A report describing CT coronary angiography findings showed extensive noncalcified plaque in the proximal left coronary artery resulting in complete focal occlusion just proximal to the origin of the first obtuse marginal artery as well as thrombotic occlusion of the proximal segment of the left circumflex artery. A case of thrombosis of the distal left anterior descending coronary artery, in the first diagonal branch, and the distal part of the dominant right coronary artery has been reported after Pfizer vaccine. Kounis’ syndrome has also been suggested as a possible explanation for acute coronary events following vaccination, which is referred to as allergic vasospastic acute coronary syndrome with or without the presence of underlying coronary artery disease. A recent study comparing coronary thromboembolic disease in those who received COVID-19 vaccine (n = 37) and those who did not (n = 52) showed that thrombus grades on coronary angiography were significantly higher in the vaccinated group.

**Pulmonary and Other Vascular Thromboembolism and Vasculitis**

Along with cerebral venous sinus thrombosis and coronary tree thrombosis, pulmonary arterial thrombosis and deep vein thrombosis (DVT) are the most common vascular complications of COVID-19 vaccines, mostly reported with AstraZeneca vaccine or Pfizer COVID-19 vaccination. DVT can be diagnosed on Doppler ultrasound (US), which demonstrates noncompressible thrombosed lumen and absence of Doppler flow in femoropopliteal and calf veins. Pulmonary CT angiography is the most appropriate modality used to diagnose PTE, with variable reported findings ranging from bilateral massive thrombosis to submassive saddle thrombosis and multiple filling defects in the segmental and subsegmental branches of both lobes and pulmonary infarcts. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a condition identified mostly with ChAdOx1 vaccine that can result in multiple-site vascular thrombosis. Other less commonly implicated vaccines include Ad26.COV2.S (Janssen; Johnson & Johnson); data are limited for the Gam-COVID-Vac/Sputnik V (Gamaleya Institute) vaccine, but a few cases have been reported. A study describing the pattern and anatomical distribution of thrombosis from 32 centers in the United Kingdom using US, CT, and MRI on 40 patients showed that the most common types of thrombosis...
Neurological Complications

The National Board of UK and Vaccine Adverse Events Reporting System (VAERS) have reported a spectrum of complications involving the central and peripheral nervous systems. Table 2 summarizes the radiological spectrum of complications involving the central and peripheral nervous systems after COVID-19 vaccination.41–68

The most common peripheral nervous system complication is Guillain–Barré syndrome (GBS) with variable imaging and clinical findings.41–46 Thickening and postcontrast enhancement of the caudal nerve roots are the most common abnormalities seen on lumbar spine MRI. Similar thickening and enhancement have been observed in the facial nerve at the fundus of the internal acoustic meatus in three cases of facial diplegia variant of GBS.47–48 Keir et al have reported enhancement and T2/fluid attenuated inversion recovery (FLAIR) hyperintensity of the olfactory nerve and bilateral olfactory tracts in a patient feeling weak, and fatigued, with random episodes of smokelike smell after receiving the second dose of Pfizer COVID-19 vaccine and progressed to hyposmia to additional odorants.50 Cases of Paronage–Turner syndrome were reported with MR neurography findings showing hyperintensity and hourglass-like constrictions of the supraspinalverve of the median and supraspinal nerves.51–55

Among the central nervous system (CNS) complications, the most frequently reported adverse event is cerebral venous sinus thrombosis, with superior sagittal and sigmoid sinuses being the most commonly thrombosed sinuses seen on MR or CT venography (Fig. 3).56,57 Cerebral dural venous thrombosis is assumed to be a manifestation of VITT, a well-recognized adverse event associated with ChAdOx1 nCov-19 vaccine (AstraZeneca). VITT is related to autoantibody generation against platelet factor four (PF4), with all the confirmed cases showing raised titers and the patients phenotypically demonstrating thrombosis in various sites. Other known, but relatively less common, adverse events are transverse myelitis, superior ophthalmic vein thrombosis, acute disseminated encephalomyelitis, multiple sclerosis, neuromyelitis optica, hemorrhagic stroke, and ischemic stroke, etc.41,42,58–68

Pulmonary Complications

Vaccine-induced interstitial lung disease (ILD) was first reported in an 86-year-old man who presented with acute onset of fever, shortness of breath, and hypoxemia requiring high-flow nasal cannula 1 day after receiving the first dose of COVID-19 mRNA vaccine in which CT of the chest showed bilateral, diffuse GGOs, with areas of focal consolidation and centrilobular nodules.69 High-dose methylprednisolone was administered, which led to rapid improvement in clinical condition and imaging findings. Other cases of ILD have been reported after mRNA vaccine, which revealed acute interstitial pneumonia pattern (bilateral diffuse GGOs) or cryptogenic organizing pneumonia (COP) pattern of opacities (X-ray showed an infiltrative shadow in the right lower lobe).70 Acute exacerbation of idiopathic pulmonary fibrosis has been reported in which CT showed bilateral GGOs, which were replaced by subpleural reticulation after steroid therapy which remained and progressed.71

Abdominal Complications

A wide spectrum of abdominal manifestations of COVID-19 vaccination has been described. These complications are assumed to be the outcome of either vaccine-associated vascular abnormalities or the consequence of vaccine-mediated autoimmune phenomenon.

The VITT can result in thrombosis of the abdominal and pelvic vessels, with the most common being portomesenteric thrombosis and systemic arterial thrombosis. CT/MR
Table 2  Radiological spectrum of complications involving the central and peripheral nervous systems after COVID-19 vaccination

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Vaccine</th>
<th>Clinical feature</th>
<th>MRI features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral nervous system</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guillain–Barré syndrome (GBS)</td>
<td>ChAdOx1 vaccine Pfizer</td>
<td>Distal paresthesia and symmetrical, progressive muscle weakness hands and feet, 10–20 d after vaccination; spontaneous recovery after 5 d</td>
<td>• Thickening and postcontrast enhancement of caudal nerve roots and pial enhancement of conus medullaris</td>
</tr>
<tr>
<td></td>
<td>Johnson &amp; Johnson, d26. COV2.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Janssen vaccine Pfizer</td>
<td>Unilateral facial droop (similar to Bell’s palsy), subjective weakness, and paresthesias in all limbs</td>
<td>• T2 hyperintensity in the median and supraspinal nerves \ • Enhancement of the bilateral internal auditory canal fundi and bilateral cisternal segments of the trigeminal nerves \ • T2 hyperintensity hourglasslike constrictions of the supraspinal nerve with edema of the supraspinatus and infraspinatus muscles</td>
</tr>
<tr>
<td></td>
<td>Johnson &amp; Johnson</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phantosmia</td>
<td>Pfizer-BioNTech vaccine</td>
<td>Fatigue, “smokelike” smell, hyposmia</td>
<td>• Enhancement and T2/FLAIR hyperintensity of olfactory nerve and bilateral olfactory tracts \ • Thickened and clumped olfactory nerve fila</td>
</tr>
<tr>
<td>Parsonage–Turner syndrome</td>
<td>mRNA-1273 Moderna BNT162b2 vaccine (Pfizer-BioNTech)</td>
<td>Persistent severe shoulder pain/cramping pain, inability to abduct shoulder</td>
<td>• T2 hyperintensity and areas of hourglasslike constriction in the median nerve in the distal arm with edema in the pronator teres \ • T2 hyperintensity hourglasslike constrictions of the supraspinal nerve with edema of the supraspinatus and infraspinatus muscles</td>
</tr>
<tr>
<td>Central nervous system</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebral sinus venous thrombosis (CVST)</td>
<td>AstraZeneca Vaxzevria vaccine</td>
<td>Severe headache, acute cerebrovascular accident 6–12 d after vaccination Patient died within 2 h–5 d</td>
<td>• Multiple subacute intra-axial hemorrhages in the frontal and temporal lobes with the vein of Galen, superior sagittal and aortic arch, and basilar artery thrombosis \ • Superior sagittal, sigmoid sinus thrombus, and diffuse cortical vein thrombosis</td>
</tr>
<tr>
<td>Transverse myelitis</td>
<td>ChAdOx1</td>
<td>2 wk after vaccination, progressive paresthesia below T4, along with lower limb weakness</td>
<td>• T2 hyperintense, intramedullary-enhancing lesion over the spinal cord at the T1–T6 vertebral levels</td>
</tr>
<tr>
<td>Infarct</td>
<td>ChAdOx1</td>
<td>10–14 d</td>
<td>• Middle cerebral artery/internal cerebral artery territory infarct with hemorrhagic transformation</td>
</tr>
<tr>
<td>ADEM</td>
<td>Pfizer vaccine Sinovac</td>
<td>2–10 wk after vaccination Seizure, hemiparesis, or progressive generalized weakness Improved after treatment</td>
<td>• Diffuse, symmetric T2 hyperintensity in the bilateral central semi-ovale, internal capsules extending through the brainstem into the bilateral cerebellar hemispheres \ • T2/FLAIR hyperintensity in unilateral cerebellar peduncle, with mass effect on the fourth ventricle \ • T2/FLAIR hyperintensity in the thalamus, bilateral corona radiata, left diencephalon, and parietal cortex</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>Pfizer-BioNTech BNT162b2</td>
<td>6 d after vaccination, sensory impairment below the T6 level Mild improvement after plasma exchange</td>
<td>• Contrast-enhancing lesion at the T6 level, T2/FLAIR hyperintense plaques (&gt;20) in the splenium, periventricular, juxtacortical region, and cerebellum</td>
</tr>
</tbody>
</table>

(Continued)
angiography is the key modality for assessment of thrombus distribution and it has been shown that inclusion of additional sites in the scan can reveal additional locations of thrombosis, especially CVT and PTE. A case report has shown a combined thrombus involving arterial (coeliac trunk, hepatic, and splenic arteries), portal (superior and inferior mesenteric veins, splenic and portal veins), and venous system (inferior vena cava and common iliac vein) in a 62-year-old patient, 1 day after receiving the first dose of vaccine (ChAdOx1-S [mfgd. by AstraZeneca] vaccine).72

Vaccine-mediated abdominal autoimmune phenomena usually present with a wide spectrum of manifestations ranging from autoimmune hepatitis to glomerular disease.73,74 COVID-19 vaccine (mostly Pfizer-BioNTech COVID-19 mRNA vaccine) associated acute pancreatitis has been reported as case reports with a variety of CT findings ranging from normal to mildly edematous pancreas (interstitial pancreatitis) with/without peripancreatic inflammation/fluid collection to pancreatic necrosis and necrotic collections. The causal association is debatable in most cases; however, using the Naranjo criteria, the

### Table 2 (Continued)

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Vaccine</th>
<th>Clinical feature</th>
<th>MRI features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Superior ophthalmic artery thrombosis</td>
<td>ChAdOx1</td>
<td>Binocular diplopia at vertical and right lateral gaze 10 d after vaccination. Patient treated and recovered 26 d after admission</td>
<td>• Bilateral high T2 signal intensity, and postcontrast filling defect in the superior ophthalmic veins</td>
</tr>
<tr>
<td>Creutzfeldt–Jakob disease</td>
<td>ChAdOx1</td>
<td>Rapidly progressive dementia with asymmetric rigidity 1 d after receiving the 2nd dose</td>
<td>• Diffusion restriction in the bilateral caudate, putamina, and cerebral cortex in the bilateral cerebral hemispheres (Fig. 4)</td>
</tr>
<tr>
<td>Rhombencephalitis</td>
<td>Pfizer/BioNTech</td>
<td>Unilateral facial paralysis, paralysis of the hypoglossal nerve, and massive ataxia of all extremities, 2 wk after vaccination</td>
<td>• FLAIR hyperintensity of the brainstem, mesencephalon, and cerebellar hemispheres around the fourth ventricle</td>
</tr>
</tbody>
</table>

Abbreviations: FLAIR; fluid attenuated inversion recovery; MRI, magnetic resonance imaging.

![Fig. 3](image)

**Fig. 3** A 33-year-old woman presented with severe headache 3 days after the first dose of ChAdOx1 vaccination. There was hemorrhagic infarct in the left thalamus extending to the midbrain (not shown). Magnetic resonance (MR) venography revealed nonvisualization of the left sigmoid sinus (arrow) indicating venous thrombosis. The right sigmoid sinus was normally seen (dashed arrows).

![Fig. 4](image)

**Fig. 4** A 65-year-old woman presented with behavioral abnormality 1 day after receiving the second dose of ChAdOx1 vaccine, which rapidly deteriorated to incoherent speech, aggravated forgetfulness, hallucinations, abnormal movements of limbs, and jaw and neck dystonia. (A) Magnetic resonance imaging (MRI) axial fluid attenuated inversion recovery (FLAIR) and (B) diffusion weighted images showed FLAIR hyperintensity (black arrows) and diffusion restriction in bilateral caudate, putamina (white arrows), and the cerebral cortex in bilateral hemispheres (curved arrows). Electroencephalogram (EEG) revealed bilateral biphasic and triphasic sharp wave periodic discharges of 1 Hz, with slowing of background activity, suggestive of Creutzfeldt-Jakob disease. Over the next 2 weeks, she developed respiratory distress and shock and died after 1 month of admission.
pancreatitis being "caused" by the COVID-19 mRNA vaccine score was probable.75–77

**Musculoskeletal Complications**

Besides cases of Parsonage–Turner syndrome, a case of inflammatory fascitis has been reported in which MRI revealed edema in the subcutaneous fascia, fluid in the sternoclavicular joint, mild supraspinatus tendinitis, and enlarged cervical nodes in a 48-year-old male patient who experienced intense pain in the left shoulder 1 day after the second dose of Pfizer-BioNTech vaccine and was unable to lift his shoulder.78 Shoulder injury related to vaccine administration (SIRVA) is a medicolegal entity first introduced in 2010 to describe shoulder pain with limited range of motion within 48 hours after various vaccine receipt in subjects with no prior symptoms.79 In regard to COVID-19 vaccination, SIRVA is considered an under-reported entity and its radiological manifestation is even more under-recognized. Vaccine-associated myositis has been described on MRI, which revealed T2 hyperintense edema of the middle head of the deltoid muscle tracking along muscle fascicles with no tear or abscess and significant enhancement on postcontrast T1 sequence.80

Several cases of COVID-19-vaccine-related arthritis have been reported after various COVID-19 vaccines (most commonly Sinovac vaccine) with varied joint involvement. The cases were polyarticular (50%) and half of all cases involved a single joint. The metacarpophalangeal (MCP), proximal interphalangeal (PIP), and distal interphalangeal (DIP) joints were involved in the majority of cases, followed by the knee, shoulder, ankle, and elbow joints. However, there is no description of radiographic/MRI findings in the reported cases of arthritis.81

**Endocrine System Complications**

Cases of subacute thyroiditis, recurrent Graves’ disease, and painless thyroiditis have been reported after Pfizer, Moderna, and AstraZeneca vaccines.82–85 In a systematic review of the US examination of 36 cases of vaccine-induced Graves’ disease, 24 showed increased vascularity on color Doppler. Of the 12 patients on whom thyroid scintigraphy was performed, the majority had an increased diffuse uptake. In subacute thyroiditis, diffusely heterogeneous thyroid was seen on US, with increased peripheral and internal vascularity on Doppler. Asymptomatic thyroiditis has also been observed after 3 weeks of receipt of AstraZeneca vaccine where US showed diffusely hypoechoic thyroid gland with reduced blood flow.

A case of vaccine-associated hypopituitarism has been reported in a patient who complained of headache, nausea, vomiting, malaise, and diffuse arthralgias 3 days after receiving the second dose of Moderna vaccine. MRI of the brain showed a diffusely enlarged pituitary gland without any focal lesion, and the imaging features were consistent with acute hypophysitis. The patient was started on glucocorticoid and thyroid hormone supplementation and showed clinical and radiological improvement. After 1 month of therapy, a follow-up MRI revealed significantly reduced pituitary size with a partially empty sella.86

Bilateral adrenal hemorrhage appearing as hyperdense bulky adrenals with adjacent fat stranding on CT has been reported after AstraZeneca vaccine administration in the setting of VITT in a patient who had features of adrenal insufficiency. Another case of VITT showed an enlarged left rounded adrenal gland, with loss of shape and decreased CT attenuation along with thrombosis in the ipsilateral renal vein, consistent with adrenal infarction and postinfarction necrosis. This patient had no clinical or biochemical evidence of adrenal insufficiency. Another case of primary adrenal insufficiency, after AstraZeneca vaccine, has been described where abdominal MRI showed bilateral adrenal nodular enlargement with T1 hyperintense peripheral halo and hypointense center suggestive of ongoing subacute bilateral adrenal hemorrhage.87–89

**Imaging Pitfalls after Vaccination**

Few case reports have intimated about intense FDG uptake in the axillary, supraclavicular, and cervical lymph nodes on FDG-PET/CT following mRNA COVID-19 vaccine after ipsilateral arm vaccination.90,91 These findings of vaccine-associated hypermetabolic lymphadenopathy (VAHL) may result in spurious interpretation in cases of related malignancies such as breast cancer, melanoma, or lymphoma as accurate nodal staging is one of the key roles of PET/CT in these cases. Therefore, it is important to carefully manage the timing of FDG-PET scans either immediately after or 4 to 6 weeks after vaccination. Nodal FDG uptake tends to occur within 7 days of vaccination and generally disappears by 12 to 14 days. A study demonstrated the potential of 68Ga fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT to avoid 18F-FDG-PET/CT postvaccination pitfalls and enable superior tumor localization. Increased FDG uptake has also been observed in the spleen after COVID-19 vaccination.92

Inflammatory changes have been seen in the ipsilateral breast of a 60-year-old woman 5 days after a booster dose of Pfizer-BioNTech vaccine on mammography seen as a new asymmetry in the upper breast that was categorized as probably a benign lesion (Breast Imaging Reporting and Data System [BI-RADS] category 3). The patient’s follow-up mammography 2 months later showed resolution of the asymmetry.93

**Conclusion**

Nearly 2 years since the onset of the expeditious and largest vaccination drive in the history of mankind, our review reiterates the efficacy of these invaluable products of modern biomedical research and provides compelling evidence in terms of morphometric involvement of the pulmonary parenchyma by COVID-19 with CT/radiographic severity scores as imaging surrogate of biological activity. While the pandemic seems to have been curbed down presently, there are still lingering concerns regarding safety and
vaccine-induced adverse effects. Familiarity with various imaging manifestations presented in this review will help physicians and radiologists to promptly identify the various cardiovascular, neurological, musculoskeletal, and endocrine complications of COVID-19 vaccines. Finally, vaccine-induced local and systemic inflammatory changes might evoke confusing imaging patterns, mimicking oncological pathology, and hence these studies should be timed according to the receipt of the last vaccine dose.

Funding
None.

Conflict of Interest
None declared.

References
1 MacDonald NESAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine 2015;33(34):4161–4164
14 Lakshia RT, Trivedi JR. The CT scan lung severity score and vaccination status in COVID-19 patients during the second wave in India: perspective of an independent radiology practice. medRxiv2021.07.15.21260597
17 Dubey R, Sen KK, Mitra A, Sethi HS, Arora R, Goyal M. Correlation of radiological findings on high-resolution computed tomography chest in vaccinated and unvaccinated COVID-19 patients from Eastern India. Indian J Respir Care 2022;11:124–127
33 Wiest NE, Johns GS, Edwards E. A case of acute pulmonary embolus after mRNA SARS-CoV-2 immunization. Vaccines (Basel) 2021;9(08):903
Triantafyllidis KK, Giannos P, Stathi D, Kechagias KS. Graves' disease following vaccination against SARS-CoV-2: a systematic review of the reported cases. Front Endocrinol (Lausanne) 2022;13:938001
Kim E, Reig B. Breast inflammatory change is transient following COVID-19 vaccination. Radiology 2022;304(03):533